NeoThetis Liquid Biopsy - Therapy Selection

NeoThetis is a novel, non-invasive liquid biopsy test for therapy selection, that guides patients diagnosed with cancer towards the most optimal treatment. NeoThetis can analyze minute amounts of circulating tumor DNA (ctDNA) which is released from primary and metastatic tumors in the bloodstream of patients. Performed via a simple blood draw, NeoThetis is safe for the patient and overcomes some of the challenges of tumor biopsy such as the need for hospitalization after surgery. • Guides therapy selection for primary and metastatic disease, and treatment re-evaluation for therapy resistance • FDA/EMA approved therapy solutions • Associated with ongoing clinical trials • Tests for clinically actionable genetic alterations, and immunotherapy eligibility • Identifies mutations in distant non-operable metastatic lesions • Captures intra- and intertumor heterogeneity, offering a comprehensive genomic tumor profiling • Offers fast turnaround results, ensuring treatment can begin faster NeoThetis tests are designed to detect clinically actionable genetic alterations, including single nucleotide variants (SNVs), insertions and deletions (INDELs), copy number amplifications (CNAs), and rearrangements that drive cancer or are associated with response to treatment. NeoThetis also tests for MSI, and bTMB predictive biomarkers that guide immunotherapy treatment. GENETIC ALTERATIONS REARRANGEMENTS CNAs SNVs, INDELs MSI bTMB TARGETED TECHNOLOGY & NOVEL BIOINFORMATICS Unparalleled workflow which combines our proprietary Targeted Capture Enrichment Technology along with novel bioinformatic pipelines, to provide accurate detection of genetic variants. Our high-read depth analysis enables for increased sensitivity and specificity providing reliable results.